论文部分内容阅读
目的探讨孟鲁司特联合氨溴特罗治疗儿童咳嗽变异性哮喘的效果和安全性。方法咳嗽变异性哮喘患儿76例,随机分为观察组39例和对照组37例。对照组给予孟鲁司特3~5mg/次,1次/d,睡前口服;观察组在对照组治疗基础上给予氨溴特罗口服液5~15mL/次,1次/d,口服;2组疗程均为14d。记录2组咳嗽及肺部啰音消失时间;比较2组治疗前、后第1秒用力呼气容积(forced expiratory volume in one second,FEV1),FEV1/用力肺活量(forced vital capacity,FVC)(FEV1/FVC)、最大呼气流量(peak expiratory flow,PEF)。结果观察组咳嗽消失时间[(6.12±1.28)d]、肺部啰音消失时间[(7.18±1.75)d]均较对照组[(9.85±2.03)、(11.03±2.17)d]缩短(P<0.05);观察组治疗后FEV1[(82.42±8.94)%]、FEV_1/FVC[(81.52±7.89)%]、PEF[(90.79±8.33)L/s]均较治疗前[(76.13±10.64)%、(75.21±10.23)%、(84.91±12.54)L/s]增高(P<0.05);对照组治疗后FEV1[(78.05±9.43)%]、FEV_1/FVC[(77.86±8.45)%]、PEF[(86.33±9.19)L/s]与治疗前[(75.89±10.49)%、(74.93±10.07)%、(84.68±12.47)L/s]比较差异无统计学意义(P>0.05);观察组治疗后各指标水平均高于对照组(P<0.05)。结论孟鲁司特联合氨溴特罗治疗儿童咳嗽变异性哮喘可明显改善患儿肺功能,缩短咳嗽及肺部啰音消失时间。
Objective To investigate the efficacy and safety of montelukast combined with ambroxol on children with cough variant asthma. Methods Sixty-six children with cough variant asthma were randomly divided into observation group (n = 39) and control group (n = 37). The control group was given montelukast 3 ~ 5mg / time, once a day, before bedtime. The observation group was treated with oral administration of ambroxol 5 ~ 15mL / time, once a day, orally; Two groups of treatment are 14d. The duration of cough and pulmonary rales disappeared were recorded. The forced expiratory volume in one second (FEV1), forced vital capacity (FEV1), FEV1 / FVC), peak expiratory flow (PEF). Results The cough disappearance time [(6.12 ± 1.28) d] and pulmonary rales disappearance time (7.18 ± 1.75 d) in the observation group were shorter than those in the control group (9.85 ± 2.03 and 11.03 ± 2.17 days, P (P <0.05). The FEV1 [(82.42 ± 8.94)%], FEV1 / FVC (81.52 ± 7.89)% and PEF [90.79 ± 8.33] L / s in the observation group were significantly higher than those before treatment [(76.13 ± 10.64 (78.05 ± 9.43)%], FEV_1 / FVC [(77.86 ± 8.45)%], (75.21 ± 10.23)% and (84.91 ± 12.54) L / ], PEF [(86.33 ± 9.19) L / s] were not significantly different from those before treatment [(75.89 ± 10.49)%, (74.93 ± 10.07)%, (84.68 ± 12.47) L / s] ); The observation group after treatment, the indicators were higher than the control group (P <0.05). Conclusion Montelukast combined with ambroxol treatment of children with cough variant asthma can significantly improve children’s lung function, shorten the cough and pulmonary rales disappear time.